US Patent Issued to Provectus Pharmatech, UTI on Aug. 5 for "In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors" (Canadian, American Inventors)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,377,068, issued on Aug. 5, was assigned to Provectus Pharmatech Inc. (Knoxville, Tenn.) and UTI LP (Calgary, Canada).

"In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors" was invented by Jamie Singer (Knoxville, Tenn.), Eric A. Wachter (Oak Ridge, Tenn.), Satbir Thakur (Calgary, Canada), Lucy Swift (Calgary, Canada), Chunfen Zhang (Calgary, Canada), Mohit Jain (Calgary, Canada) and Aru Narendran (Calgary, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an ...